For research teamsHelp me find a study
Back to all studies
CompletedNCT06068465

Pimavanserin tartrate for Parkinson's Disease Psychosis

This study is completed in China. It is testing pimavanserin tartrate for Parkinson's Disease Psychosis.

SchizophreniaDrugOver 40 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT06068465. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

Check the official registry

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

China · 27 sites
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui
    Site status: Not listed — confirm with the team
  • Beijing Hospital
    Beijing, Beijing Municipality
    Site status: Not listed — confirm with the team
  • Xuan Wu Hospital
    Beijing, Beijing Municipality
    Site status: Not listed — confirm with the team
  • Peking University Sixth Hospital
    Beijing, Beijing Municipality
    Site status: Not listed — confirm with the team
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality
    Site status: Not listed — confirm with the team
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian
    Site status: Not listed — confirm with the team
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong
    Site status: Not listed — confirm with the team
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou
    Site status: Not listed — confirm with the team
  • The Second Hospital of HeBei Medical University
    Shijiazhuang, Hebei
    Site status: Not listed — confirm with the team
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan
    Site status: Not listed — confirm with the team
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan
    Site status: Not listed — confirm with the team
  • Inner Mongolia Autonomous Region People's Hospital
    Hohhot, Inner Mongolia
    Site status: Not listed — confirm with the team
  • Huai'an Second People's Hospital
    Huaian, Jiangsu
    Site status: Not listed — confirm with the team
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu
    Site status: Not listed — confirm with the team
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu
    Site status: Not listed — confirm with the team
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu
    Site status: Not listed — confirm with the team
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu
    Site status: Not listed — confirm with the team
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi
    Site status: Not listed — confirm with the team
  • The First Hospital of Jilin University
    Changchun, Jilin
    Site status: Not listed — confirm with the team
  • The First Hospital of China Medical University
    Shenyang, Liaoning
    Site status: Not listed — confirm with the team
  • People's Hospital of Ningxia Hui Autonomous Region
    Yinchuan, Ningxia
    Site status: Not listed — confirm with the team
  • Qilu Hospital of Shandong University
    Jinan, Shandong
    Site status: Not listed — confirm with the team
  • Qilu Hospital of Shandong University(Qingdao)
    Qingdao, Shandong
    Site status: Not listed — confirm with the team
  • Ruijin Hospital
    Shanghai, Shanghai Municipality
    Site status: Not listed — confirm with the team
  • West China Hospital of Sichuan University
    Chengdu, Sichuan
    Site status: Not listed — confirm with the team
  • Mianyang Central Hospital
    Mianyang, Sichuan
    Site status: Not listed — confirm with the team
  • Tianjin Huanhu Hospital
    Tianjin, Tianjin Municipality
    Site status: Not listed — confirm with the team
In plain English

Key information made simple

What is this study testing?

This study is testing whether the Safety and Efficacy of Pimavanserin may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive the Safety and Efficacy of Pimavanserin, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in China.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: September 27, 2024
Recruitment status
Completed
Enrollment listed in the registry
248
Sponsor
Tasly Pharmaceutical Group Co., Ltd
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
China
Age range
Over 40 Years
Official registry ID
NCT06068465
Official title
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT06068465. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving pimavanserin tartrate, placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: Over 40 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Tasly Pharmaceutical Group Co., Ltd, which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.